Eli Lilly’s Next-gen $6.5B API and GLP-1 Orforglipron Facility, Houston, Texas, USA
Eli Lilly and Company has announced plans to build a $6.5 billion next-generation active pharmaceutical ingredient (API) manufacturing facility at
Read moreEli Lilly and Company has announced plans to build a $6.5 billion next-generation active pharmaceutical ingredient (API) manufacturing facility at
Read moreGlobal biopharmaceutical leader AstraZeneca has officially opened a new $300 million state-of-the-art cell therapy manufacturing facility in Rockville, Maryland, marking
Read moreIn a transformative move for the U.S. healthcare manufacturing sector, Roche unveiled plans to invest $50 billion in American pharmaceutical
Read moreIn a significant acquisition move, pharmaceutical giant MSD has agreed to acquire the WuXi Vaccines manufacturing facility in Dundalk, Ireland.
Read moreInfrareal Holding plans to take over Takeda’s pharma and biotech site specialising in gene and cell therapies in Orth, Lower
Read moreJohnson & Johnson has announced a significant investment exceeding $2 billion to establish a cutting-edge biologics manufacturing facility in Wilson,
Read moreThrough the strategic acquisition of Eli Lilly’s San Diego ‘Life Science Studio’, Arctoris’ has doubled the size of its existing
Read moreEli Lilly and Company has announced that it has more than doubled its investment in its Lebanon, Indiana, USA manufacturing
Read moreIn a strategic move to bolster its global supply of antibody-drug conjugates (ADCs), AstraZeneca has announced the development of a
Read moreThe Behring Campus Eystrup is a cutting-edge research facility specialising in animal immunology, antibody development, and preclinical research. Located at
Read more